Data showed 43 percent and 44 percent of patients taking two different doses were symptom-free for the two years compared to 16 percent of patients receiving placebo
The study included seven dose cohorts, with a total of 41 patients receiving either placebo or single doses of ARRY-403 ranging from 25 mg to 400 mg...Genmab A/S, of Copenhagen, and GlaxoSmithKline plc, of London, reported top-line results from a Phase II study of Arzerra (ofatumumab) in combination with fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia patients, showing a complete remission rate of 32 percent in patients receiving the 500-mg Arzerra regimen and
Pharmasset Inc., of Princeton, N.J., said preliminary results from a Phase I study showed that PSI-7851, a second-generation nucleotide polymerase inhibitor of hepatitis C virus, demonstrated antiviral activity, with a mean HCV RNA decrease of -0.49 log10 IU/mL, -.61 log10 IU/mL and -1.01 log10 IU/mL in patients receiving once daily doses of 50 mg, 100 mg and 200 mg, respectively, for three days
Some 84.6 percent of study patients receiving one injection of serum-free HSC showed an increase in terminal hair 12 weeks post-injection, with a statistically significant increase in the number of terminal hairs, cumulative hair thickness density and hair thickness mean
The 35-patient trial included 27 patients receiving MAXY-G34 of dosages of 10, 30, 45, 60 or 100 mcg/kg and eight patients receiving Amgen Inc.'s Neulasta (pegfilgrastim) at a fixed dose of 6 mg
A Clinic Roundup item in BioWorld Today, July 14, 2009, should have said Prana Biotechnology Ltd.'s Phase IIa data showed that 41 percent of patients receiving PBT2 had substantial cognitive improvement vs. 4 percent on placebo
A top-line analysis of data from the trial indicated that patients receiving cobiprostone experienced a lower overall incidence of ulcers...At week 12, patients receiving the 54-mcg dose experienced a 50 percent reduction in the overall incidence of gastric ulcers when compared to patients taking placebo
Upon approval of the drug, the company said it intended to continue the program as part of a patient care program designed to assist, support and educate patients receiving prGCD therapy
Melogliptin significantly reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.75 percent in patients receiving 50-mg twice-daily doses and 0.60 percent in patients receiving 100-mg once-daily doses...The study population has been modified to evaluate patients receiving first-line chemotherapy, rather than those receiving second-line chemotherapy
Theratechnologies Inc., of Montreal, reported results from a pharmacokinetic/pharmacodynamic evaluation of tesamorelin after single and multiple administrations of 2 mg once daily for 14 consecutive days, in healthy volunteers and HIV-positive patients receiving stable antiretroviral regimens
Mean time to first repeat paracentesis following a baseline procedure was 55 days with aflibercept, compared with 23 days for patients receiving placebo (p = 0.0019
Johnson & Johnson, of New Brunswick, N.J., said a new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis who had prior treatment with antitumor necrosis factor-alpha agents and who received subcutaneous injections of Simponi (golimumab) once every four weeks experienced significant improvements in signs and symptoms through week 24, compared with patients receiving placebo
In 177 patients receiving radiotherapy for inoperable NSCLC, the randomized, double-blind, placebo-controlled trial assessed the radio-enhancing activity and safety of perifosine co-administration
Centocor Ortho Biotech Inc., of Horsham, Pa., and Schering-Plough Corp., of Kenilworth, N.J., said long-term findings from a Phase IIIb SONIC study in patients with moderately to severely active Crohn's disease showed that a greater proportion of those receiving Remicade (infliximab) maintained steroid-free remission at one year, compared to patients receiving the immune suppressant azathioprine alone
Logical Therapeutics Inc., of Waltham, Mass., and Medinox Inc., of Carlsbad, Calif., said a double-blind trial comparing naproxen prodrug LT-NS001 to naproxen showed that patients receiving LT-NS001 experienced significantly fewer endoscopically confirmed gastric ulcers...The subset of patients receiving only topical corticosteroids, which were tapered between weeks four and 16 did, in fact, flare, while the 0.4 mg/kg LX211 dose group did to a much lesser extent
Of the 12 patients receiving KRN5500, eight had improved pain scores with one patient showing 100 percent improvement and four having no change in pain response
The study revealed higher blood levels of docetaxel during and immediately following infusion of the study drug in patients receiving ANX-514 relative to those getting Taxotere, but at 10 minutes after the completion of infusion, docetaxel blood levels were comparable and remained so through the end of the observation period
Agile Therapeutics Inc., of Princeton, N.J., reported data showing that patients receiving AG200-15, its low-dose weekly contraceptive patch, had consistent ethinyl estradiol (EE) and levonorgestrel hormone levels over three cycles and within range of low-dose oral contraceptives
Data showed 43 percent and 44 percent of patients taking two different doses were symptom-free for the two years compared to 16 percent of patients receiving placebo